Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease
/PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today...
United States Psulagna Bhattacharya Laszloz Bito Stephen Tsang Aaron Osborne Prnewswire Nanoscope Therapeutics Inc
Source: prnewswire.com